This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this article the students from the University of Florida discuss why they started the ChatRx podcast and what their goals are for their new endeavor. Written By: Eisha Ludtke, Pharm.D. Candidate 2024 & Lucas Zhou, Pharm.D. Candidate 2024 Article Posted October 2024 Hello Readers of IDstewardship! My name is Eisha Ludtke, and I am a 4th year pharmacy student at the University of Florida (UF).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Meta founder Mark Zuckerberg and his wife, pediatrician and philanthropist Priscilla Chan, announced on Wednesday plans to invest $250 million over 10 years to establish a new “biohub” in New York City focused on building a new class of cellular machines that can surveil the body and snuff out disease. The new initiative, publicly revealed at the 2023 STAT Summit and previewed exclusively to STAT, is the latest program from the Chan Zuckerberg Initiative, or CZI, a company the coup
Stephen Hemsley, the former CEO of UnitedHealth Group and its current board chair, also owns an investment firm that manages his own portfolio of UnitedHealth stock and oversees other wealthy individuals’ accounts that have held shares of companies that have direct business with or indirect ties to United. It’s an unusual arrangement for someone in such a prominent role at one of the largest health care corporations in the world, according to several experts in securities and corpo
Stephen Hemsley, the former CEO of UnitedHealth Group and its current board chair, also owns an investment firm that manages his own portfolio of UnitedHealth stock and oversees other wealthy individuals’ accounts that have held shares of companies that have direct business with or indirect ties to United. It’s an unusual arrangement for someone in such a prominent role at one of the largest health care corporations in the world, according to several experts in securities and corpo
As pharmacists provide more health care services, opportunities arise for more sophisticated patient engagement and billing solutions that drive patient satisfaction and increased loyalty.
There’s a specter haunting Wall Street. It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.
Seniors are forced to navigate a convoluted Medicare Advantage (MA) landscape for healthcare coverage, often only to be denied care, experts told legislators during a Senate Finance Committee heari | Senators and experts agreed Wednesday that marketing practices from Medicare Advantage plans are often overwhelming for seniors.
Laurie Glimcher trained at Massachusetts General Hospital. Her father was the chair of orthopedic surgery there, and her son is currently a thoracic surgeon at the hospital. But Glimcher, the CEO of the neighboring Dana-Farber Cancer Institute , has no qualms about the contentious decision to sever a 30-year partnership with Massachusetts General’s parent organization.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Senate Finance Committee members from both parties took aim Wednesday at insurance brokers that sell plans for large Medicare Advantage insurers. Older adults at times have more than 100 plan options, and brokers help them choose the right one. But brokers can be incentivized by large insurance companies to aggressively sell plans that are a poor fit for the Medicare beneficiaries they’re supposed to help.
Back in the 1990s, scientist Lotte Bjerre Knudsen was tasked with revitalizing a floundering program at Novo Nordisk that had been trying to harness the newly-discovered GLP-1 hormone into viable diabetes drug candidates. At the time, many of Knudsen’s bosses had already lost hope for the program. Novo’s focus, after all, was on insulin, and the naturally occurring GLP-1 hormone had too short a half-life to use as a drug.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Following the results of a meta-analysis that reviewed biosimilar trial design and endpoints, investigators urge for greater biosimilar uptake initiatives.
DALLAS — Treatments like Ozempic, Wegovy, and Mounjaro have been hailed for showing 15% to over 20% weight loss in trials, but those are just averages. In reality, there are big variations in how much weight people lose on the therapies, and it’s unclear what explains those differences. One way researchers are trying to figure this out is by focusing on genes.
During a nearly two-decade stint as Alnylam’s founding CEO, John Maraganore took a promising but unproven approach for treating genetic disease and built a new class of medicines and what is now a nearly $21 billion company. His next goal? Helping the next generation of budding biotech entrepreneurs. Since stepping down as Alnylam CEO in 2021, Maraganore has spent much of his time passing down his knowledge to up-and-coming biotech CEOs.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
At the age of 26, Lauren Ghazal was diagnosed with Hodgkin’s lymphoma just months into her Ph.D. program in nursing theory at New York University. She experienced firsthand how the financial burden of undergoing cancer treatment, along with the emotional and physical toll of the disease itself, can lead to overwhelming distress in patients. Now, as an assistant professor at the University of Rochester in the School of Nursing, she researches health and quality of life outcomes among young
Grace Yun, PharmD, and pharmacy manager at St. Francis Hospital, discussed the value of the pharmacist and how she sees the future of pharmacy evolving.
Since the early days of the pandemic, long Covid has haunted us: Even a mild acute infection might leave you with life-altering consequences. And for many, that has, sadly, turned out to be the case. While research suggests long Covid rates are falling, it still affects millions. In June 2023, 6% of Americans reported experiencing long Covid. But what if long Covid isn’t the right way to think about what they are going through?
Medically integrated dispensing specialty pharmacies can connect patient medical and pharmacy records to improve medication adherence and help patients to safely stay on them for longer.
Among drugmakers, big pharma has a reputation of being stodgy and old-fashioned, while biotech startups are seen as rife with fresher thinking — companies where innovative solutions are actually hatched and are then acquired by those older, bigger firms. But at the STAT Summit on Wednesday, Daniel Skovronsky, the chief scientific and medical officer at Eli Lilly, discussed how Lilly has been able to crack both obesity and Alzheimer’s , two areas that have long stumped drug develope
Henry Ford Health is coming together with several of Ascension Michigan’s hospitals and other facilities to form a joint venture with over $10.5 billion in annual operating revenue, the organizatio | Should the deal close, the resulting organization would span 13 acute care hospitals and over 550 sites of care. The nonprofits stressed that the arrangement is not a merger and that "no cash transaction" would take place.
Areas of focus for specialty medications include biosimilars, cancer treatments, and drugs across disease states such as inflammatory conditions, HIV, and multiple sclerosis.
PLCOm2012 uses additional parameters to predict the risk of lung cancer and was found more effective when identifying both Indigenous and non-Indigenous individuals with lung cancer.
Twice-daily tenapanor tablets are recommended for patients with chronic kidney disease who are on dialysis, unresponsive or intolerant of any dose of a phosphate binder therapy.
The US Food and Drug Administration (FDA) has approved XPHOZAH ® (tenapanor), the first and only phosphate absorption inhibitor. Ardelyx’s first-in-class oral treatment is indicated to reduce serum phosphorus in adults with chronic kidney disease ( CKD ) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant to phosphate binder therapy.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
182 
Let's personalize your content